AbbVie succeeds in late-stage migraine treatment trial

AbbVie (NYSE:ABBV) said on Wednesday that its late-stage study testing atogepant in comparison with the highest dose of topiramate for migraine treatment met the main goal.

This study focused on adults who typically experience four or more migraine days each month.

The company said that atogepant successfully achieved its main goal in the study, showing fewer patients discontinuing treatment due to adverse events compared to topiramate, marketed as topamax by Johnson & Johnson (JNJ).

Additionally, the trial successfully achieved all six secondary endpoints.

It showed that 64.1% of participants taking atogepant experienced a reduction of 50% or more in their average monthly migraine days during the fourth to sixth months of the double-blind treatment period, compared to 39.3% of those on topiramate.

Atogepant, which is available under the brand names Aquipta in the EU and Qulipta in the U.S., Canada, Israel, and Puerto Rico, holds approval in a total of 60 countries.

The safety profile of atogepant observed in this study was generally in line with earlier trials, the company added.